WALTHAM, MA, USA I July 28, 2025 I Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has ...

US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with Galapagos Purchase price is $55m in cash to be paid upon consummation of the sale with up ...

Indication SEPHIENCE is indicated for the treatment of hyperphenylalaninemia (HPA) in adult and pediatric patients 1 month of age and older with sepiapterin-responsive phenylketonuria (PKU). SEPHIENCE ...

PARIS, France I July 28, 2025 I Genethon, a worldwide pioneer and leader in research and development in gene therapy for rare genetic diseases, has received ...

Matchpoint to receive up to $60 million in upfront payment and research funding, with up to $1 billion in total potential payments, including option exercise ...

LONDON, UK I July 28, 2025 I GSK plc (LSE/NYSE: GSK) today announced it has entered into agreements with Hengrui Pharma (600276.SH; 01276.HK) to develop up to ...

BOLOGNA, Italy I July 28, 2025 I Alfasigma S.p.A today announced positive topline results from the OLINGUITO Phase 3 clinical trial (NCT05785611; Eudra CT ...

NEW ORLEANS, LA, USA I July 28, 2025 I South Rampart Pharma, Inc., a clinical-stage biopharmaceutical company focused on innovative non-opioid pain therapies, ...

Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements.

COPENHAGEN, Denmark I July 28, 2025 I Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Administration (FDA) has approved ...

DAEJEON, South Korea I July 28, 2025 I Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal ...

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% becoming amyloid PET negative ...